TGFB1 and cancer: Through inhibiting AGTR1, losartan and its analogs can decrease the levels of decrease transforming growth factor-β (TGF-β) activators such as thromboplastin-1 (TSP-1) to reduce the quantity of TGF-β, thus inhibiting the synthesis of type I collagen derived from cancer-associated fibroblasts (CAFs) to reduce the proliferation of connective tissues [82].